文献速递淋巴瘤造血干细胞移植与细胞治疗

高危经典型霍奇金淋巴瘤成人患者自体造血干细胞移植后维布妥昔单抗联合纳武利尤单抗:多中心2期试验

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2022-11-17

这项在美国5个中心开展的多中心2期试验纳入59例高危复发或难治性经典型霍奇金淋巴瘤成人患者,在自体造血干细胞移植后30-60天开始给予维布妥昔单抗(1·8 mg/kg)联合纳武利尤单抗(3 mg/kg),每21天1个周期,最多8个周期;全部59例患者18个月无进展生存率为94%(95%CI 84-98),未观察到治疗相关死亡。

要点

  • 移植后中位54天启动联合治疗,中位随访29·9个月,18个月无进展生存率94%(95%CI 84-98)。
  • 最常见不良事件为感觉性周围神经病(31/59,53%)和中性粒细胞减少(25/59,42%)。
  • 需糖皮质激素治疗的免疫相关不良事件见于17/59(29%),未观察到治疗相关死亡。

核心结论

  • 维布妥昔单抗联合纳武利尤单抗作为高危复发或难治性经典型霍奇金淋巴瘤患者自体造血干细胞移植后的巩固治疗具有高度活性,多数患者既往曾暴露于维布妥昔单抗或PD-1阻断。
  • 作者认为该情境下的联合免疫治疗应进一步研究,并进一步优化方案以减轻毒性,尤其在高危患者中,这类患者需要更强化的治疗来预防复发。

研究设计与样本

  • 多中心2期试验,在美国5个中心开展,注册号ClinicalTrials.gov NCT03057795。
  • 纳入18岁及以上、高危复发或难治性经典型霍奇金淋巴瘤、ECOG体能状态0-2分且器官和骨髓功能足够的患者,共59例入组并接受研究治疗。
  • 给予维布妥昔单抗(1·8 mg/kg)联合纳武利尤单抗(3 mg/kg)静脉给药,自自体造血干细胞移植后30-60天开始,每21天周期的第1天给药,最多8个周期;不允许纳武利尤单抗减量,维布妥昔单抗可减量至1·2 mg/kg;因毒性停用一种药物时另一种可继续。
  • 主要终点为全部接受治疗患者的18个月无进展生存率。

主要发现

  • 2017年5月3日至2019年7月13日入组59例患者并接受研究治疗;患者于自体造血干细胞移植后中位54天(IQR 46-58)开始维布妥昔单抗联合纳武利尤单抗,中位接受8个周期(8-8)。
  • 59例中34例(58%)为男性;29例(49%)完成8个周期维布妥昔单抗联合纳武利尤单抗,45例(76%)完成至少一种药物的8个周期。
  • 中位随访时间29·9个月(IQR 24·6-34·8);全部59例患者18个月无进展生存率为94%(95%CI 84-98)。
  • 最常见不良事件为感觉性周围神经病(31/59,53%)和中性粒细胞减少(25/59,42%);需糖皮质激素治疗的免疫相关不良事件发生于17/59(29%)患者;未观察到治疗相关死亡。

关键数值与推荐

  • 维布妥昔单抗剂量为1·8 mg/kg,纳武利尤单抗剂量为3 mg/kg,静脉给药,每21天周期第1天,最多8个周期。
  • 维布妥昔单抗可减量至1·2 mg/kg;不允许纳武利尤单抗减量。
  • 治疗自自体造血干细胞移植后30-60天开始;主要终点为18个月无进展生存率。

临床怎么用

  • 作者认为维布妥昔单抗联合纳武利尤单抗作为高危复发或难治性经典型霍奇金淋巴瘤患者自体造血干细胞移植后的巩固治疗具有高度活性。
  • 作者认为该情境下的联合免疫治疗应进一步研究,并进一步优化方案以减轻毒性,尤其在高危患者中,这类患者需要更强化的治疗来预防复发。

局限性

  • 原文在解释部分提出联合免疫治疗应进一步研究并进一步优化方案以减轻毒性,尤其在高危患者中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After autologous haematopoietic stem-cell transplantation (HSCT), consolidation with brentuximab vedotin in patients with high-risk relapsed or refractory classic Hodgkin lymphoma has been shown to improve progression-free survival compared with placebo. Brentuximab vedotin plus nivolumab is a safe and effective treatment for relapsed or refractory classic Hodgkin lymphoma; therefore, we aimed to evaluate the safety and activity of this drug combination post-autologous HSCT consolidation in patients with high-risk relapsed or refractory classic Hodgkin lymphoma. METHODS: We did a multicentre phase 2 trial at five centres in the USA. Eligible patients were aged 18 years or older with high-risk relapsed or refractory classic Hodgkin lymphoma, had an ECOG performance status of 0-2, and had adequate organ and bone marrow function. Enrolled patients received brentuximab vedotin (1·8 mg/kg) and nivolumab (3 mg/kg) intravenously starting 30-60 days after autologous HSCT on day 1 of each 21-day cycle for up to 8 cycles. Nivolumab dose reduction was not allowed. Brentuximab vedotin dose reduction to 1·2 mg/kg was permitted. If one drug was discontinued because of a toxic effect, the other could be continued. The primary endpoint was 18-month progression-free survival in all treated patients. This study is registered with ClinicalTrials.gov, number NCT03057795. FINDINGS: Between May 3, 2017, and July 13, 2019, 59 patients were enrolled and received the study therapy. Patients initiated brentuximab vedotin plus nivolumab for a median of 54 days (IQR 46-58) after autologous HSCT and received a median of 8 cycles (8-8). 34 (58%) of 59 patients were male, 29 (49%) completed 8 cycles of brentuximab vedotin plus nivolumab, and 45 (76%) completed 8 cycles of at least one drug. The median follow-up time was 29·9 months (IQR 24·6-34·8). The 18-month progression-free survival in all 59 patients was 94% (95% CI 84-98). The most common adverse events were sensory peripheral neuropathy (31 [53%] of 59) and neutropenia (25 [42%]), and immune-related adverse events requiring corticosteroids occurred in 17 (29%) of 59 patients. No treatment-related deaths were observed. INTERPRETATION: Brentuximab vedotin plus nivolumab was highly active post-autologous HSCT consolidation for patients with high-risk relapsed or refractory classic Hodgkin lymphoma, most of whom had previous exposure to either brentuximab vedotin or PD-1 blockade. Combination immunotherapy in this setting should be further studied in patients with classic Hodgkin lymphoma with further refinement of the regimen to mitigate toxic effects, particularly in high-risk patients in whom more intensive therapy to prevent relapse is warranted. FUNDING: Bristol Myers Squibb, Leukemia and Lymphoma Society, Lymphoma Research Foundation, and National Cancer Institute of the National Institutes of Health.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Herrera AF, Chen L, Nieto Y, et al. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2022. PMID: 36403579. doi:10.1016/S2352-3026(22)00318-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。